FDA Announces Draft Guidance on Outsourcing Facility Sales - Quarles
FDA issued draft guidance on outsourcing facility sales, potentially affecting how compounding pharmacies and other outsourcing facilities handle sales and distribution.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 11, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Outsourcing facilities (including compounding pharmacies) that sell or distribute products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New draft guidance from FDA regarding sales practices for outsourcing facilities.
Who it affects
Outsourcing facilities (including compounding pharmacies) that sell or distribute products.
What you must do
Review the draft guidance to understand proposed changes and prepare for potential compliance adjustments.
Deadline
Not specified in the excerpt.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- New Jersey Pharmacies Will Soon Be Able to Sell Birth Control Without a Prescription | Publications | Insights - Faegre Drinker
- Changes Coming For Prescribers To The Texas Prescription Drug Monitoring Program - JD Supra
- Illinois PBM Law to Limit Steering, Other Plan Design Features in 2026 - ogletree.com
- Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com